Changes in serum calcium and vitamin D₃ levels after tibolone treatment and their correlations with health-related quality of life.

What Was Tested

This clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

To assess the effects of tibolone on serum calcium and vitamin D3 levels, the effects on health-related quality of life (HRQOL), and the relationship between these variables.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, women only.

Women aged 34-55 years were eligible when they were experiencing surgical menopause and were symptomatic.

How the Study Was Run

In design terms this was an open-label and parallel-group study.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

An open-label, prospective, parallel-arm study was conducted at S.C.

Das Memorial Medical and Research Center, Kolkata, India, between July 2012, and June 2013.

At baseline and 6 months, body mass index (BMI), serum calcium and vitamin D3 levels and HRQOL were assessed.

What Was Measured

PubMed files the paper under topics including Calcium, Cholecalciferol, Estrogen Receptor Modulators, India, Menopause, Norpregnenes and Quality of Life.

Author keywords: Tibolone and Vitamin D(3).

What This Means in Plain Language

The paper is an open-label and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.